The Right Molecule: STX-101

History of STX-101

Alosetron is FDA-Approved for Severe IBS-D in Women

However, severe safety risks and restricted use criteria limit market adoption

STX-101’s Partial Agonism Resolves Safety Challenges

STX-101 Shows Efficacy in FGID Model Comparable to Alosetron

Phase 1 Studies Conducted

Phase 1 Results

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept